NasdaqCM - Delayed Quote USD

Inovio Pharmaceuticals, Inc. (INO)

10.13 +0.36 (+3.68%)
At close: May 31 at 4:00 PM EDT
10.30 +0.17 (+1.68%)
After hours: May 31 at 7:02 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
717.07
832.01
10,262.27
1,774.76
7,411.22
--
Operating Expense
121,676.52
134,258.67
277,835.79
302,992.68
131,493.26
--
Operating Income
-120,959.45
-133,426.66
-267,573.52
-301,217.92
-124,082.04
--
Net Non Operating Interest Income Expense
6,339.28
6,910.50
3,528.08
1,426.63
-5,390.60
--
Other Income Expense
-10,317.73
-8,601.20
-13,607.41
-3,433.04
-33,417.66
--
Pretax Income
-124,937.91
-135,117.35
-277,652.85
-303,224.32
-162,890.30
--
Tax Provision
--
--
--
--
--
-257.34
Earnings from Equity Interest Net of Tax
--
--
-2,165.21
-434.39
-4,584.61
--
Net Income Common Stockholders
-124,937.91
-135,117.35
-279,818.07
-303,658.71
-166,411.16
--
Diluted NI Available to Com Stockholders
-124,937.91
-135,117.35
-279,818.07
-303,658.71
-166,411.16
--
Basic EPS
-5.51
-6.09
-14.07
-17.45
-12.84
--
Diluted EPS
-5.51
-6.09
-14.07
-17.45
-12.84
--
Basic Average Shares
22,612.42
22,173.66
19,885.18
17,402.48
12,927.24
--
Diluted Average Shares
22,612.42
22,173.66
19,885.18
17,402.48
12,927.24
--
Total Operating Income as Reported
-131,472.82
-143,940.03
-267,573.52
-301,217.92
-124,082.04
--
Total Expenses
121,676.52
134,258.67
277,835.79
302,992.68
131,493.26
--
Net Income from Continuing & Discontinued Operation
-124,937.91
-135,117.35
-279,818.07
-303,658.71
-166,411.16
--
Normalized Income
-117,557.82
-130,454.61
-271,971.89
-300,435.87
-97,141.74
--
Interest Income
7,426.41
8,133.29
4,782.03
3,363.08
3,311.85
--
Interest Expense
1,087.13
1,222.79
1,253.95
1,936.45
8,702.45
--
Net Interest Income
6,339.28
6,910.50
3,528.08
1,426.63
-5,390.60
--
EBIT
-123,850.77
-133,894.56
-276,398.90
-301,287.88
-154,187.85
--
EBITDA
-120,739.63
-130,391.03
-270,902.87
-296,557.10
-149,560.06
--
Reconciled Depreciation
3,111.14
3,503.54
5,496.03
4,730.78
4,627.79
--
Net Income from Continuing Operation Net Minority Interest
-124,937.91
-135,117.35
-279,818.07
-303,658.71
-166,411.16
--
Total Unusual Items Excluding Goodwill
-7,380.08
-4,662.75
-7,846.17
-3,222.84
-69,269.42
--
Total Unusual Items
-7,380.08
-4,662.75
-7,846.17
-3,222.84
-69,269.42
--
Normalized EBITDA
-113,359.55
-125,728.28
-263,056.70
-293,334.26
-80,290.65
--
12/31/2019 - 12/8/1998

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

VXRT Vaxart, Inc.
0.8150
+0.14%
 
NVAX Novavax, Inc.
15.03
-1.44%
 
SRNE Sorrento Therapeutics, Inc.
0.0113
-22.07%
 
IBIO iBio, Inc.
2.3800
+6.73%
 
OCGN Ocugen, Inc.
1.7300
+8.81%
 
BNTX BioNTech SE
100.60
+1.87%
 
VBIV VBI Vaccines Inc.
0.6125
+1.91%
 
CVAC CureVac N.V.
3.8900
+3.18%
 
MRNA Moderna, Inc.
142.55
-5.90%
 
ALT Altimmune, Inc.
7.51
+6.98%